EP
HAE icon

Essential Partners’s Haemonetics HAE Stock Holding History

Essential Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87.1K Sell
1,161
-525
-31% -$33.7K 0.04% 456
2026
Q1 		$95K Sell
1,686
-11
-0.6% -$716 0.03% 435
2025
Q4 		$136K Buy
1,697
+716
+73% +$48.1K 0.04% 380
2025
Q3 		$47.8K Buy
981
+907
+1,226% +$56.1K 0.02% 603
2025
Q2 		$5.52K Buy
+74
New +$4.9K ﹤0.01% 1022

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's HAE Position: Q2 2026 in Review

Essential Partners reduced its Haemonetics (HAE) stake by 31% in Q2 2026, selling an estimated $33.7K and leaving 1,161 shares worth $87.1K. The position accounts for 0.04% of the portfolio, ranked #456.

Essential Partners first reported a position in HAE in Q2 2025 and has held it in 5 quarters since. The position peaked at $136K in Q4 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Essential Partners held 1,161 shares of Haemonetics worth $87.1K as of Q2 2026.
  • Essential Partners sold 525 Haemonetics shares in Q2 2026, an estimated $33.7K.
  • Haemonetics made up 0.04% of Essential Partners's portfolio in Q2 2026, its #456 holding.
  • Essential Partners first reported a position in Haemonetics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Haemonetics position peaked at $136K in Q4 2025.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.